Compare AstraZeneca plc (AZN) vs Beyond Meat Inc (BYND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Beyond Meat Inc — how do they compare? AstraZeneca plc trades at $158.09 (market cap $248.14B), while Beyond Meat Inc trades at $0.41 (market cap $215.41M). The key difference: AstraZeneca plc is far larger — about 1151.9× Beyond Meat Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Beyond Meat Inc pays none. Which is the better fit depends on your goals.
| AZN | BYND | |
|---|---|---|
Market Cap | $248.14B | $215.41M |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $3.62 |
52-Week Low | $147.06 | $0.42 |
Enterprise Value | $275.41B | $455.69M |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Beyond Meat (BYND) trades at $0.52, down 3.29% amid bearish technical signals and recent reverse stock split. The company shows mixed fundamentals with revenue declining from $419M in 2022 to $275M in 2025, though net income turned positive at $178M in 2025 with a 64.6% margin. Technical indicators show bearish momentum with moving averages signaling sell and ADX confirming strong downtrend, while RSI remains neutral. Recent news highlights stock collapse to all-time lows following the 30:1 reverse split announcement in August 2026.
Investment outlook remains highly risky with 57% analyst sell ratings and persistent cash burn from operations. While valuation ratios appear attractive (P/S 0.61, EV/EBITDA 1.28), declining revenue and negative operating cash flow (-$145M in 2025) challenge sustainability. The turnaround strategy focusing on international expansion faces execution risks amid competitive pressures and consumer demand uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
